Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zavesca
Miglustat is an iminosugar that inhibits glucosylceramide synthase, an enzyme essential for the synthesis of most glycosphingolipids. It is used to treat certain types of lysosomal storage disorders, specifically Niemann-Pick disease type C and Gaucher disease type 1. Miglustat belongs to the class of glucosylceramide synthase inhibitors.
For the treatment of Niemann-Pick disease type C and certain forms of Gaucher disease type 1.
Outcome:
Decreased miglustat levels
Mechanism:
Induction of CYP3A4
Outcome:
May increase miglustat levels
Mechanism:
Inhibition of CYP3A4
Outcome:
May decrease miglustat absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Sustained-release oral formulation (2025, 80% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of miglustat being approved for additional indications related to glycosphingolipid storage disorders within the next 5 years.
Glucosylceramide Synthase Inhibitor, Iminosugar
Iminosugar